Anthony D. Elias, MD, on Triple-Negative Breast Cancer: PARP Inhibitors in the Current Treatment Landscape

Posted: Thursday, April 12, 2018

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews the role of PARP inhibitors in the current treatment landscape for triple-negative breast cancer and the implications of the now-approved olaparib for gBRCA-mutant breast cancer.